PHREESIA INC
PHRNYSETrading Snapshot
- Day Range
- $12.21 β $12.47
- 52-Week Range
- $7.77 β $23.87
- Volume (shares)
- 28,022
- Avg Volume (shares)
- β
- Shares Outstanding
- 62.1M
- Next Earnings
- 2026-12-07
Fundamentals Snapshot
- Annual Revenue
- $481M
- Last Q Revenue
- $129M
- P/E Ratio
- 73.6
- P/S Ratio
- 1.5x
- EPS (TTM)
- $0.17
- Dividend Yield
- β
- Dilution (1yr)
- +1.6%
PHREESIA INC
PHRAbout PHREESIA INC
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Head-To-Head Comparison: Phreesia (NYSE:PHR) & National Research (NASDAQ:NRC)
National Research (NASDAQ: NRC - Get Free Report) and Phreesia (NYSE: PHR - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the st

Phreesia's Michael Rasbury Named to Becker's 2026 List of Rising Stars: Healthcare Leaders Under 40
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia's Michael Rasbury, VP of AccessOne Solutions, named to Becker's Hospital Review's 2026 Rising Stars: Healthcare Leaders Under 40 list.

Phreesia Named to TIME's 2026 List of the World's Top HealthTech Companies
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to TIME's list of the World's Top HealthTech Companies of 2026. This marks the second co

Phreesia (NYSE:PHR) General Counsel Allison Hoffman Sells 6,662 Shares of Stock
Phreesia, Inc. (NYSE: PHR - Get Free Report) General Counsel Allison Hoffman sold 6,662 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $10.08, for a total val

Phreesia's ProviderConnect Audiences are Now Available in the DeepIntent Audience Marketplace
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia's ProviderConnect audiences are now available in the DeepIntent Audience Marketplace.

Why Phreesia Stock Got Knocked Down Today
This added to lingering negative sentiment following the company's latest earnings release. Investors didn't like the fact that it whiffed on earnings.